This strategic report provides a comprehensive, professional, and plagiarism-free analysis of the Global NGS-based RNA-seq Market. It incorporates advanced segmentation, technical shifts, and strategic frameworks for the 2025–2036 forecast period.
Global NGS-based RNA-seq Market Strategic Report (2025–2036)
Market Overview
The Global Next-Generation Sequencing (NGS)-based RNA-seq Market is the backbone of modern transcriptomics, providing unprecedented insights into the functional elements of the genome. Valued at USD [XXXX] Million in 2025, the market is anticipated to reach USD [XXXX] Million by 2036, growing at a CAGR of [XX.X]%.
RNA-seq has largely superseded microarray technology due to its higher dynamic range, ability to detect novel transcripts, and single-nucleotide resolution. The market is currently being reshaped by three major pillars: the transition from bulk to single-cell RNA sequencing (scRNA-seq), the emergence of spatial transcriptomics, and the rapid adoption of long-read sequencing technologies to resolve complex isoforms.
Expanded Market Segmentation
By Product & Service
-
Sequencing Platforms: High-throughput (benchtop and production-scale) instruments.
-
Reagents & Consumables: Library preparation kits, flow cells, and enzymes.
-
Sequencing Services: Third-party providers for end-to-end RNA analysis.
-
Bioinformatics & Software: Data analysis pipelines, visualization tools, and cloud-based storage/management solutions.
By Technology
-
Short-Read RNA-seq: Dominated by synthesis-by-sequencing (SBS); ideal for expression profiling and quantification.
-
Long-Read RNA-seq: Utilizing nanopore and SMRT technology to sequence full-length transcripts without fragmentation.
-
Spatial Transcriptomics: Mapping gene expression within the original tissue context.
By Application
-
Expression Profiling: Differential gene expression analysis for disease versus healthy states.
-
Transcriptome Assembly: De novo assembly and structural annotation of non-model organisms.
-
Variant Discovery: Identifying SNVs, Indels, and fusion genes within the transcriptome.
-
Small RNA Sequencing: Analysis of miRNA, siRNA, and other non-coding RNAs.
-
Single-Cell RNA-seq: Understanding cellular heterogeneity in oncology and developmental biology.
By End-User
-
Pharmaceutical & Biotechnology Companies: Target identification and biomarker discovery.
-
Academic & Research Institutes: Fundamental genomic research and clinical studies.
-
Hospitals & Diagnostic Centers: Precision oncology and rare disease diagnostics.
Key Players (Global Leaders & Specialized Innovators)
-
Illumina, Inc. (USA)
-
Thermo Fisher Scientific Inc. (USA)
-
Pacific Biosciences of California, Inc. (PacBio) (USA)
-
Oxford Nanopore Technologies plc (UK)
-
10x Genomics, Inc. (USA)
-
BGI Group (MGI Tech) (China)
-
QIAGEN N.V. (Netherlands)
-
Agilent Technologies, Inc. (USA)
-
F. Hoffmann-La Roche Ltd. (Switzerland)
-
Novogene Co., Ltd. (China)
-
Revvity (PerkinElmer) (USA)
-
Nanostring Technologies (USA)
-
Eurofins Scientific (Luxembourg)
-
Macrogen, Inc. (South Korea)
-
Takara Bio Inc. (Japan)
Regional Analysis
-
North America: The largest market share holder, driven by a high density of biotech hubs, substantial NIH funding, and rapid clinical adoption of RNA-based diagnostics.
-
Europe: A mature market focusing on large-scale population genomics projects and stringent data privacy standards (GDPR) affecting genomic storage.
-
Asia-Pacific: The highest CAGR region. Growth is fueled by massive government investments in precision medicine in China, the expanding clinical diagnostics market in India, and advanced genomic research in Japan.
-
LAMEA: Emerging markets focusing on agricultural genomics and localized infectious disease monitoring.
Porter’s Five Forces Analysis
-
Threat of New Entrants (Moderate): While the barrier for hardware is high, many startups are entering via specialized library prep kits and AI-driven bioinformatics software.
-
Bargaining Power of Buyers (Moderate to High): Large research core facilities and pharma companies can negotiate bulk pricing on consumables.
-
Bargaining Power of Suppliers (High): Specialized enzymes and high-purity chemicals are sourced from a few key global providers.
-
Threat of Substitutes (Low): Microarrays are fading, and there is currently no viable technological alternative to NGS for high-resolution transcriptome wide-scale analysis.
-
Competitive Rivalry (High): Intense competition between short-read (Illumina) and long-read (Oxford Nanopore/PacBio) technologies for dominance in isoform discovery.
SWOT Analysis
-
Strengths: Unrivaled sensitivity; ability to detect non-coding RNA; falling cost per gigabase of data.
-
Weaknesses: Massive data storage requirements; complexity of bioinformatic analysis for non-experts.
-
Opportunities: Development of RNA-based liquid biopsies for cancer screening; integration of AI for automated transcript annotation.
-
Threats: Ethical and regulatory concerns regarding genetic data ownership; high cost of single-cell and spatial technologies limiting access in developing regions.
Strategic Trend Analysis
-
The Single-Cell Revolution: scRNA-seq is becoming a standard requirement for publications, allowing researchers to see "which cell says what" rather than an average of the whole tissue.
-
Direct RNA Sequencing: Moving away from cDNA synthesis to sequence the original RNA molecule directly, preserving epigenetic modifications like m6A.
-
Multi-omics Integration: Combining RNA-seq data with proteomics and epigenomics (ATAC-seq) to provide a 360-degree view of biological systems.
Drivers & Challenges
-
Driver: The rise of Personalized Medicine, where RNA-seq is used to select the most effective immunotherapy for oncology patients.
-
Driver: Rapidly decreasing costs of sequencing, making large-scale population studies financially viable.
-
Challenge: The Bioinformatic Bottleneck—the ability to generate data has outpaced the general scientific community's ability to analyze and interpret it.
-
Challenge: Sample quality—RNA is inherently unstable, making high-quality library preparation difficult for degraded samples like FFPE (Formalin-Fixed Paraffin-Embedded) tissues.
Value Chain Analysis
-
Upstream: R&D of sequencing enzymes, flow cells, and high-performance computing hardware.
-
Midstream: Sample collection, RNA extraction, and library preparation (automated vs. manual).
-
Downstream: High-speed sequencing runs and raw data generation.
-
End-Market: Bioinformatics interpretation, clinical diagnostic reports, and pharmaceutical drug-target validation.
Quick Recommendations for Stakeholders
-
For Manufacturers: Focus on automation-friendly library prep. As throughput increases, manual preparation becomes a liability for lab efficiency.
-
For Research Institutes: Invest in Long-Read infrastructure. While short-reads are great for counting, long-reads are essential for understanding the complexity of splicing and isoforms.
-
For Investors: Target the Spatial Transcriptomics niche. It is currently the most significant growth area, bridging the gap between pathology and genomics.
-
For Clinicians: Implement Standardized Bioinformatic Pipelines to ensure that RNA-seq data is reproducible and actionable for patient care.
1. Market Overview of NGS-based RNA-seq
1.1 NGS-based RNA-seq Market Overview
1.1.1 NGS-based RNA-seq Product Scope
1.1.2 Market Status and Outlook
1.2 NGS-based RNA-seq Market Size by Regions:
1.3 NGS-based RNA-seq Historic Market Size by Regions
1.4 NGS-based RNA-seq Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact NGS-based RNA-seq Sales Market by Type
2.1 Global NGS-based RNA-seq Historic Market Size by Type
2.2 Global NGS-based RNA-seq Forecasted Market Size by Type
2.3 Sample Preparation
2.4 Sample Preparation
2.5 by Method
2.6 Sequencing Platforms & Consumables for RNA-Seq
2.7 RNA Sequencing Services
2.8 Data Analysis
2.9 Storage
2.10 and Management
3. Covid-19 Impact NGS-based RNA-seq Sales Market by Application
3.1 Global NGS-based RNA-seq Historic Market Size by Application
3.2 Global NGS-based RNA-seq Forecasted Market Size by Application
3.3 De Novo Transcriptome Assembly
3.4 Expression Profiling Analysis
3.5 Variant Calling and Transcriptome Epigenetics
3.6 Small RNA Sequencing
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global NGS-based RNA-seq Production Capacity Market Share by Manufacturers
4.2 Global NGS-based RNA-seq Revenue Market Share by Manufacturers
4.3 Global NGS-based RNA-seq Average Price by Manufacturers
5. Company Profiles and Key Figures in NGS-based RNA-seq Business
5.1 Illumina
5.1.1 Illumina Company Profile
5.1.2 Illumina NGS-based RNA-seq Product Specification
5.1.3 Illumina NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.2 Thermo Fisher Scientific
5.2.1 Thermo Fisher Scientific Company Profile
5.2.2 Thermo Fisher Scientific NGS-based RNA-seq Product Specification
5.2.3 Thermo Fisher Scientific NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.3 Pacific Biosciences of California
5.3.1 Pacific Biosciences of California Company Profile
5.3.2 Pacific Biosciences of California NGS-based RNA-seq Product Specification
5.3.3 Pacific Biosciences of California NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.4 QIAGEN
5.4.1 QIAGEN Company Profile
5.4.2 QIAGEN NGS-based RNA-seq Product Specification
5.4.3 QIAGEN NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.5 BGI
5.5.1 BGI Company Profile
5.5.2 BGI NGS-based RNA-seq Product Specification
5.5.3 BGI NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.6 Oxford Nanopore Technologies
5.6.1 Oxford Nanopore Technologies Company Profile
5.6.2 Oxford Nanopore Technologies NGS-based RNA-seq Product Specification
5.6.3 Oxford Nanopore Technologies NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.7 PerkinElmer
5.7.1 PerkinElmer Company Profile
5.7.2 PerkinElmer NGS-based RNA-seq Product Specification
5.7.3 PerkinElmer NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.8 GATC Biotech
5.8.1 GATC Biotech Company Profile
5.8.2 GATC Biotech NGS-based RNA-seq Product Specification
5.8.3 GATC Biotech NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.9 Agilent Technologies
5.9.1 Agilent Technologies Company Profile
5.9.2 Agilent Technologies NGS-based RNA-seq Product Specification
5.9.3 Agilent Technologies NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.10 Roche
5.10.1 Roche Company Profile
5.10.2 Roche NGS-based RNA-seq Product Specification
5.10.3 Roche NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.11 Macrogen
5.11.1 Macrogen Company Profile
5.11.2 Macrogen NGS-based RNA-seq Product Specification
5.11.3 Macrogen NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
5.12 Eurofins Scientific
5.12.1 Eurofins Scientific Company Profile
5.12.2 Eurofins Scientific NGS-based RNA-seq Product Specification
5.12.3 Eurofins Scientific NGS-based RNA-seq Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America NGS-based RNA-seq Market Size
6.2 North America NGS-based RNA-seq Key Players in North America
6.3 North America NGS-based RNA-seq Market Size by Type
6.4 North America NGS-based RNA-seq Market Size by Application
7. East Asia
7.1 East Asia NGS-based RNA-seq Market Size
7.2 East Asia NGS-based RNA-seq Key Players in North America
7.3 East Asia NGS-based RNA-seq Market Size by Type
7.4 East Asia NGS-based RNA-seq Market Size by Application
8. Europe
8.1 Europe NGS-based RNA-seq Market Size
8.2 Europe NGS-based RNA-seq Key Players in North America
8.3 Europe NGS-based RNA-seq Market Size by Type
8.4 Europe NGS-based RNA-seq Market Size by Application
9. South Asia
9.1 South Asia NGS-based RNA-seq Market Size
9.2 South Asia NGS-based RNA-seq Key Players in North America
9.3 South Asia NGS-based RNA-seq Market Size by Type
9.4 South Asia NGS-based RNA-seq Market Size by Application
10. Southeast Asia
10.1 Southeast Asia NGS-based RNA-seq Market Size
10.2 Southeast Asia NGS-based RNA-seq Key Players in North America
10.3 Southeast Asia NGS-based RNA-seq Market Size by Type
10.4 Southeast Asia NGS-based RNA-seq Market Size by Application
11. Middle East
11.1 Middle East NGS-based RNA-seq Market Size
11.2 Middle East NGS-based RNA-seq Key Players in North America
11.3 Middle East NGS-based RNA-seq Market Size by Type
11.4 Middle East NGS-based RNA-seq Market Size by Application
12. Africa
12.1 Africa NGS-based RNA-seq Market Size
12.2 Africa NGS-based RNA-seq Key Players in North America
12.3 Africa NGS-based RNA-seq Market Size by Type
12.4 Africa NGS-based RNA-seq Market Size by Application
13. Oceania
13.1 Oceania NGS-based RNA-seq Market Size
13.2 Oceania NGS-based RNA-seq Key Players in North America
13.3 Oceania NGS-based RNA-seq Market Size by Type
13.4 Oceania NGS-based RNA-seq Market Size by Application
14. South America
14.1 South America NGS-based RNA-seq Market Size
14.2 South America NGS-based RNA-seq Key Players in North America
14.3 South America NGS-based RNA-seq Market Size by Type
14.4 South America NGS-based RNA-seq Market Size by Application
15. Rest of the World
15.1 Rest of the World NGS-based RNA-seq Market Size
15.2 Rest of the World NGS-based RNA-seq Key Players in North America
15.3 Rest of the World NGS-based RNA-seq Market Size by Type
15.4 Rest of the World NGS-based RNA-seq Market Size by Application
16 NGS-based RNA-seq Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Expanded Market Segmentation
By Product & Service
-
Sequencing Platforms: High-throughput (benchtop and production-scale) instruments.
-
Reagents & Consumables: Library preparation kits, flow cells, and enzymes.
-
Sequencing Services: Third-party providers for end-to-end RNA analysis.
-
Bioinformatics & Software: Data analysis pipelines, visualization tools, and cloud-based storage/management solutions.
By Technology
-
Short-Read RNA-seq: Dominated by synthesis-by-sequencing (SBS); ideal for expression profiling and quantification.
-
Long-Read RNA-seq: Utilizing nanopore and SMRT technology to sequence full-length transcripts without fragmentation.
-
Spatial Transcriptomics: Mapping gene expression within the original tissue context.
By Application
-
Expression Profiling: Differential gene expression analysis for disease versus healthy states.
-
Transcriptome Assembly: De novo assembly and structural annotation of non-model organisms.
-
Variant Discovery: Identifying SNVs, Indels, and fusion genes within the transcriptome.
-
Small RNA Sequencing: Analysis of miRNA, siRNA, and other non-coding RNAs.
-
Single-Cell RNA-seq: Understanding cellular heterogeneity in oncology and developmental biology.
By End-User
-
Pharmaceutical & Biotechnology Companies: Target identification and biomarker discovery.
-
Academic & Research Institutes: Fundamental genomic research and clinical studies.
-
Hospitals & Diagnostic Centers: Precision oncology and rare disease diagnostics.
Key Players (Global Leaders & Specialized Innovators)
-
Illumina, Inc. (USA)
-
Thermo Fisher Scientific Inc. (USA)
-
Pacific Biosciences of California, Inc. (PacBio) (USA)
-
Oxford Nanopore Technologies plc (UK)
-
10x Genomics, Inc. (USA)
-
BGI Group (MGI Tech) (China)
-
QIAGEN N.V. (Netherlands)
-
Agilent Technologies, Inc. (USA)
-
F. Hoffmann-La Roche Ltd. (Switzerland)
-
Novogene Co., Ltd. (China)
-
Revvity (PerkinElmer) (USA)
-
Nanostring Technologies (USA)
-
Eurofins Scientific (Luxembourg)
-
Macrogen, Inc. (South Korea)
-
Takara Bio Inc. (Japan)
